It wasn’t too long ago that Prosensa Holding was kicked to the curb by Wall Street investors. Following a failed Phase 3 trial for its Duchenne Muscular Dystrophy (Read more...)
N30 Pharmaceuticals, a Boulder-based pharmaceutical company developing drugs for cystic fibrosis, announced yesterday it has raised a $30 million mezzanine financing round. N30 Pharma will use the (Read more...)
Shares of Clovis Oncology dropped 10 percent this morning following the release of interim results for the ongoing trial of the company’s drug for lung cancer patients.
Analysts (Read more...)
Vertex Pharmaceuticals has developed a drug that has changed the way cystic fibrosis is treated for some patients with a specific genetic mutation. And now the non-profit organization (Read more...)
Agios Pharmaceuticals turned heads in April when it showed its first drug prospect might be able to treat a devastating blood cancer, acute myeloid leukemia (AML), in people (Read more...)
Scientists at The Scripps Research Institute have produced the first 3-D image of how the ZMapp drug developed by San Diego’s Mapp Biopharmaceutical binds to the Ebola (Read more...)
ONL Therapeutics, a University of Michigan spin-out biopharmaceutical startup working on sight-preserving therapies for retinal diseases, announced today that it has won a $1.3 million Small (Read more...)
Venture capital funding for startups in the San Diego area ticked up slightly during the third quarter that ended Sept. 30, with $238.5 million invested in (Read more...)
Venture capital activity is down from a 13-year high during the second quarter, but a new MoneyTree Report released today shows that venture funding was still going (Read more...)
Venture capital activity descended from the stratosphere during the third quarter, but it was still flying high, as venture firms invested nearly $9.8 billion in 879 (Read more...)
Savara Pharmaceuticals has raised $10 million in a bridge loan to further evaluate its drug candidate for cystic fibrosis.
The therapy, called AeroVanc, is designed to be the ...
Japan’s Daiichi Sankyo has agreed to acquire San Diego cancer drug developer Ambit Biosciences (NASDAQ: AMBI) for $315 million in cash, with additional milestone payments that ...
Giant pharmaceutical companies have spent billions of dollars trying to crack Alzheimer’s disease, only to come up empty time after time. For small, cash-strapped biotechs, the challenge is ...
The heat wave broke with impeccable timing, and we were grateful that “California weather” was back as San Diego’s innovation leaders gathered for Xconomy’s ...
San Diego’s Avalon Ventures is taking the wraps off two new startups today, with each one getting as much as $10 million in Series A financing through ...